Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | BRD4 | O60885 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6614810 | 0.86 | POLB (0.49) | KMT2AL3MBTL1HPGDTSHRMEN1 | |
| SCHEMBL855237 | 0.71 | — | — | |
| SCHEMBL512220 | 0.71 | — | — | |
| SCHEMBL11683297 | 0.68 | ALDH1A1 (0.68) | KMT2AL3MBTL1HPGDLMNAMEN1 | |
| SCHEMBL13631426 | 0.68 | HPGD (0.71) | MAPK1L3MBTL1HPGDTSHRPOLB | |
| SCHEMBL162548 | 0.67 | CA9 (0.46) | KMT2AL3MBTL1HDAC4HDAC6HPGD | |
| SCHEMBL13753317 | 0.67 | ALDH1A1 (0.73) | MAPK1KMT2AL3MBTL1HPGDMAPT | |
| SCHEMBL29332952 | 0.67 | MAPK1 (0.50) | MAPK1KMT2AL3MBTL1HPGDTSHR | |
| SCHEMBL13702379 | 0.67 | KMT2A (0.51) | MAPK1KMT2AHDAC4HDAC1HDAC6 | |
| SCHEMBL5909057 | 0.66 | CA12 (0.58) | KMT2AL3MBTL1HDAC4HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622464-B2 | Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | claimed |
| EP-1487828-B1 | MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMATORY DISEASES | GLAXO GROUP LTD (GB) | 2008-11-05 | — | — | EP | claimed |
| US-20060063765-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-03-23 | — | — | US | claimed |
| EP-1487827-A1 | ANTI-INFLAMMATORY MORPHOLIN-ACETAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2004-12-22 | — | — | EP | claimed |
| EP-1487828-A2 | MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2004-12-22 | — | — | EP | claimed |
| WO-2003082861-A2 | MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-10-09 | — | — | WO | claimed |
| WO-2003082862-A1 | ANTI-INFLAMMATORY MORPHOLIN-ACETAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-10-09 | — | — | WO | claimed |
| US-7622464-B2 | Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | disclosed |
| EP-1487828-B1 | MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMATORY DISEASES | GLAXO GROUP LTD (GB) | 2008-11-05 | — | — | EP | disclosed |
| US-20060063765-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-03-23 | — | — | US | disclosed |
| EP-1487827-A1 | ANTI-INFLAMMATORY MORPHOLIN-ACETAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2004-12-22 | — | — | EP | disclosed |
| EP-1487828-A2 | MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003082862-A1 | ANTI-INFLAMMATORY MORPHOLIN-ACETAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003082861-A2 | MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063765-A1 | Novel compounds | CCR3, NSUN3, CCR1 | MAPK1 2559/4885KMT2A 4033/4885L3MBTL1 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.